Usefulness of empagliflozin versus oral semaglutide for prevention of cardiovascular mortality in patients with type 2 diabetes mellitus
Hammerman A, Moore CM, Aboalhasan E, et al.
Am J Cardiol. 2022;S0002-9149(22)00093-5.
Leggi
Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial
Lam CSP, Ramasundarahettige C, Branch KRH, et al.
Circulation. 2022;145(8):565-574.
Leggi
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Stefan N, Cusi K
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00003-1.
Leggi
Prediabetes blunts DPP4 genetic control of postprandial glycaemia and insulin secretion
Patarrão RS, Duarte N, Penha-Gonçalves C, et al.
Diabetologia. Pub. online 22 February 2022.
Leggi
FDA APPROVA EMPAGLIFLOZIN NELL’INSUFFICIENZA CARDIACA INDIPENDENTEMENTE DALLA FRAZIONE D’EIEZIONE
24/02/2022
Leggi
Home use of mini-dose glucagon as a novel treatment for hypoglycemia following repeated, prolonged fasts in type 1 diabetes during ramadan
Algeffari M, Hussain S, Almogbel T, et al.
Diabetes Care. 2022;dc211655.
Leggi
Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection
Yan X, Song JF, Zhang L, Li X
BMC Endocr Disord. 2022;22(1):46.
Leggi
Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER
Shaman AM, Bain SC, Bakris GL, et al.
Circulation. 2022;145(8):575-585.
Leggi
Instructive lessons from the analysis of assistance in diabetes during the first phase of COVID 19 pandemic
Giorda CB, Picariello R, Landriscina T, Tartaglino B, Nada E, Doglio M, Romeo F, Gnavi R
Acta Diabetol. Punb. online 19 February2022
Leggi
Corriere della Sera – L’editoriale del Presidente AMD
Carissimi Soci, oggi attraverso le parole del nostro Presidente, Graziano Di Cianni, siamo ospiti sulle pagine del Corriere della Sera, nell’inserto Salute, per portare all’attenzione dell’opinione pubblica e degli addetti ai lavori i punti fermi della nostra diabetologia e di quello che auspichiamo venga realizzato con le risorse del PNRR muovendo…
Leggi